Get the Stockscreener App
22.93
3.90%
-0.93
After Hours:
23.07
0.14
+0.61%
Palvella Therapeutics Inc stock is traded at $22.93, with a volume of 66,061.
It is down -3.90% in the last 24 hours and down -4.38% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$23.86
Open:
$23.366
24h Volume:
66,061
Relative Volume:
0.85
Market Cap:
$258.85M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.18%
1M Performance:
-4.38%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$21.86
$23.67
1-Week Range:
$21.86
$25.45
52-Week Range:
$11.17
$29.27
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
22.93 | 258.85M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Renaissance Technologies LLC Buys New Holdings in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 - GlobeNewswire
Leading Rare Skin Disease Biotech Palvella Makes Nasdaq Debut with Opening Bell Ceremony - Stock Titan
Geode Capital Management LLC Invests $171,000 in Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 - StreetInsider
Why Palvella Therapeutics, Inc. (PVLA) is Surging in 2025 - Yahoo Finance
Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference - MyChesCo
One Palvella Therapeutics Insider Raised Their Stake In The Previous Year - Yahoo Finance
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics Highlights Significant Estimates of Lymphatic Malformations with Cutaneous Involvement in Upcoming SID Presentation - Nasdaq
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatolo - GlobeNewswire
Groundbreaking Research Uncovers 93,000 Lymphatic Malformation Cases in U.S.First Complete Analysis - Stock Titan
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MyChesCo
Palvella Therapeutics secures new patent for rare skin disease gel By Investing.com - Investing.com South Africa
Palvella Says US Patent Granted for Qtorin Gel to Treat Rare Skin Disorder - marketscreener.com
Palvella Therapeutics secures new patent for rare skin disease gel - Investing.com
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of - Bluefield Daily Telegraph
Palvella Therapeutics Granted Additional U.S. Patent for - GlobeNewswire
FDA Breakthrough Therapy Gets Extended Patent Protection for Rare Disease Treatment Until 2038 - Stock Titan
Brokerages Set Palvella Therapeutics (NASDAQ:PVLA) Price Target at $44.43 - Defense World
Independent Chairman of the Board of Palvella Therapeutics George Jenkins Buys 1.4% More Shares - simplywall.st
What is Chardan Capital’s Estimate for PVLA FY2025 Earnings? - Defense World
Q BioMed (OTCMKTS:QBIO) versus Palvella Therapeutics (NASDAQ:PVLA) Head to Head Contrast - Defense World
Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder - MyChesCo
Palvella CEO to Present at Healthcare Innovation Conference - MSN
New Qtorin Rapamycin Data Featured at World Congress of Pediatric Dermatology - Dermatology Times
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg Scho - GlobeNewswire
Breakthrough Treatment Achieves Perfect Response Rate in Rare Disease TrialFDA Fast Track Drug Shows Promise - Stock Titan
Palvella Therapeutics (PVLA) – Analysts’ Weekly Ratings Changes - Defense World
Palvella Therapeutics director George Jenkins buys $100,797 in stock - Investing.com
Palvella Therapeutics director George Jenkins buys $100,797 in stock By Investing.com - Investing.com India
Palvella Therapeutics Director George M Jenkins Buys Shares - TradingView
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Chardan Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Chardan sets $50 target on Palvella Therapeutics stock By Investing.com - Investing.com Canada
Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target - MarketScreener
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development - GlobeNewswire Inc.
Q1 EPS Estimate for Palvella Therapeutics Lowered by Analyst - Defense World
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Rare Disease Breakthrough: Palvella CEO Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MSN
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology - The Manila Times
Groundbreaking Phase 3 Results: First-Ever Treatment for Rare Lymphatic Disease Heads to Major Congress - Stock Titan
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright - Defense World
Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? - Insider Monkey
Palvella Therapeutics (PVLA) Receives a Buy from Scotiabank - The Globe and Mail
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):